Menu
23/04/2014
Nice To Block New Breast Cancer Drug
The National Institute for Health and Care Excellence (Nice) is moving to block a new breast cancer drug because it said it is not effective enough to justify the price the NHS is being asked to pay.
The clinical trial results allegedly show that women on Kadcyla treatment survived 30.9 months. compared with 25.1 months on similar treatments, and it is currently given to breast cancer patients who have failed on conventional treatment with Herceptin and chemotherapy.
The medicine, which is manufactured by Roche, will cost around £90,000 per patient.
Nice chief executive Sir Andrew Dillon said: "We apply as much flexibility as we can in approving new treatments, but the reality is that given its price and what it offers to patients, it will displace more health benefit which the NHS could achieve in other ways than it will offer to patients with breast cancer."
Professor Paul Ellis, lead triallist for the drug in the UK and consultant oncologist at King's College. London said: "Kadcyla represents a significant advance in HER2-positive breast cancer, so for Nice to issue negative preliminary guidance is a huge blow.”
While Jayson Dallas, general manager of Roche Products Limited, said: "Roche is extremely disappointed that Nice has failed to safeguard the interests of patients with this advanced stage of aggressive disease."
The decision is now up for public consultation and during this time patients will be able to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug.
(CVS)
The clinical trial results allegedly show that women on Kadcyla treatment survived 30.9 months. compared with 25.1 months on similar treatments, and it is currently given to breast cancer patients who have failed on conventional treatment with Herceptin and chemotherapy.
The medicine, which is manufactured by Roche, will cost around £90,000 per patient.
Nice chief executive Sir Andrew Dillon said: "We apply as much flexibility as we can in approving new treatments, but the reality is that given its price and what it offers to patients, it will displace more health benefit which the NHS could achieve in other ways than it will offer to patients with breast cancer."
Professor Paul Ellis, lead triallist for the drug in the UK and consultant oncologist at King's College. London said: "Kadcyla represents a significant advance in HER2-positive breast cancer, so for Nice to issue negative preliminary guidance is a huge blow.”
While Jayson Dallas, general manager of Roche Products Limited, said: "Roche is extremely disappointed that Nice has failed to safeguard the interests of patients with this advanced stage of aggressive disease."
The decision is now up for public consultation and during this time patients will be able to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug.
(CVS)
Related UK National News Stories
Click here for the latest headlines.
08 August 2011
Cancer Survivors 'Should Exercise', Charity Claims
More than a million cancer survivors could be putting themselves at risk of long-term health problems because they are not physically active enough, a report by Macmillan Cancer Support has claimed. The charity's report, Move More, said that of the two million cancer survivors in the UK, around 1.
Cancer Survivors 'Should Exercise', Charity Claims
More than a million cancer survivors could be putting themselves at risk of long-term health problems because they are not physically active enough, a report by Macmillan Cancer Support has claimed. The charity's report, Move More, said that of the two million cancer survivors in the UK, around 1.
24 August 2010
Cancer Drug Too Expensive For NHS
Campaigners say they have been let down after a health watchdog refused a life saving drug for bowel cancer to be available on the NHS. The National Institute for Health and Clinical Excellence (NICE) rejected Roche's drug Avastin (bevacizumab), which can help patients with advanced bowel cancer, claiming it was too expensive.
Cancer Drug Too Expensive For NHS
Campaigners say they have been let down after a health watchdog refused a life saving drug for bowel cancer to be available on the NHS. The National Institute for Health and Clinical Excellence (NICE) rejected Roche's drug Avastin (bevacizumab), which can help patients with advanced bowel cancer, claiming it was too expensive.
04 February 2009
Kidney Cancer Drug Given Green Light
A drug, which prolongs the life of kidney cancer sufferers, has been given the go-ahead for patients in England and Northern Ireland, in a U-turn move. The National Institute for Health and Clinical Excellence (NICE) - the NHS drugs watchdog - published revised guidance on the drug Sutent (sunitinib).
Kidney Cancer Drug Given Green Light
A drug, which prolongs the life of kidney cancer sufferers, has been given the go-ahead for patients in England and Northern Ireland, in a U-turn move. The National Institute for Health and Clinical Excellence (NICE) - the NHS drugs watchdog - published revised guidance on the drug Sutent (sunitinib).
08 August 2014
NICE Criticises Cost Of New Breast Cancer Drug
NICE, the NHS drugs advisory body, has advised that a new breast cancer treatment not be routinely used in England. The National Institute for Health and Care Excellence (NICE) has criticised the drugs manufacturer, Roche, over the price of the drug – Kadcyla. It is understood that the treatment costs approximately £90,000 per patient.
NICE Criticises Cost Of New Breast Cancer Drug
NICE, the NHS drugs advisory body, has advised that a new breast cancer treatment not be routinely used in England. The National Institute for Health and Care Excellence (NICE) has criticised the drugs manufacturer, Roche, over the price of the drug – Kadcyla. It is understood that the treatment costs approximately £90,000 per patient.
22 September 2008
Scottish Government Pledges Cap On Surgery Waiting Times
Scottish patients may soon have a legal guarantee that they will wait no longer than 12 weeks for surgery. The Scottish Government's Patient Rights Bill proposes a strict limit on how long they have to wait from their surgical referral to receiving their operation.
Scottish Government Pledges Cap On Surgery Waiting Times
Scottish patients may soon have a legal guarantee that they will wait no longer than 12 weeks for surgery. The Scottish Government's Patient Rights Bill proposes a strict limit on how long they have to wait from their surgical referral to receiving their operation.
-
Northern Ireland WeatherToday:Gale, coastal severe gale, northwest winds ease from late afternoon. Scattered showers will fall as snow over the hills at first, becoming isolated from mid-afternoon. Maximum temperature 7 °C.Tonight:Showers, scattered in the evening, will clear by midnight leaving the night dry with clear spells. Cloud will spread east towards morning. Minimum temperature 2 °C.
